STRO - SUTRO BIOPHARMA, INC.
IEX Last Trade
1.865
0.025 1.340%
Share volume: 10,045
Last Updated: Fri 27 Dec 2024 06:30:06 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.40%
PREVIOUS CLOSE
CHG
CHG%
$1.84
0.03
1.36%
Fundamental analysis
25%
Profitability
25%
Dept financing
17%
Liquidity
74%
Performance
15%
Performance
5 Days
3.21%
1 Month
-25.77%
3 Months
-44.54%
6 Months
-34.35%
1 Year
-54.16%
2 Year
-71.91%
Key data
Stock price
$1.86
DAY RANGE
$1.83 - $1.96
52 WEEK RANGE
$1.92 - $6.13
52 WEEK CHANGE
-$55.73
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: William J. Newell
Region: US
Website: sutrobio.com
Employees: 240
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: sutrobio.com
Employees: 240
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Sutro Biopharma, Inc. focuses on creating protein therapeutics for cancer and autoimmune disorders. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma.
Recent news